2026 SITC Biotech Strategic Meeting at the NYSE

Friday, June 26 at the New York Stock Exchange

Early Registration Discount Ends May 18

Join investors and leaders from biotechnology, biopharma, academia, and regulatory agencies for high-level strategic dialogue on the future of cancer immunotherapy.

Register Now

The 2026 SITC Biotech Strategic Meeting at the New York Stock Exchange is supported, in part, by: BioNTech US Inc, Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc, BioCytics and Carolina BioOncology Institute, Dana-Farber Cancer Institute, Lumanity, Lytix Biopharma, Miltenyi Biotec B.V. & Co. KG, Numenos, Replimune Inc., Xilio Therapeutics (supporters as of April 15, 2026).

Gold Supporter

BioNTech US Inc

Gold Supporter

Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc

Biotech Community Member

BioCytics Inc and Carolina BioOncology Institute

Biotech Community Member

Dana-Farber Cancer Institute

Biotech Community Member

Lumanity

Biotech Community Member

Lytix Biopharma

Biotech Community Member

Miltenyi Biotec B.V. & Co. KG

Biotech Community Member

Numenos

Biotech Community Member

Replimune Inc.

Biotech Community Member

Xilio Therapeutics

Thank you to our program organizers.

David Kaufman, MD, PhD
Program Co-Chair
David Kaufman, MD, PhD
Third Rock Ventures
Holger Kissel, PhD
Program Co-Chair
Holger Kissel, PhD
Jarrett Rieger, Esq
Jarrett Rieger, Esq
Moffitt Cancer Center
Alexandra Snyder, MD
SITC Biotech Committee Co-Chair
Alexandra Snyder, MD
Merck
Zhen Su, MD, MBA
Program Co-Chair
Zhen Su, MD, MBA
Marengo Therapeutics
Kasia Urbanska, PhD
Kasia Urbanska, PhD
Bristol Myers Squibb

Program Description

The annual biotech strategic meeting at the NYSE convenes a highly curated group of biotech executives, investors and drug development leaders to explore the most pressing strategic questions shaping the future of immuno-oncology.

The program will feature discussions on late-stage and commercial biotech strategy, emerging modalities such as in vivo cell therapies, AI-enabled drug development and the evolving global regulatory and financing landscape.

Designed to foster meaningful dialogue and high-value connections, this forum offers a unique opportunity to engage directly with leaders driving innovation and deal making across the biotech ecosystem.

Program Schedule

2026 SITC Biotech Strategic Meeting at the NYSE

Friday, June 26, 2026 · New York Stock Exchange

Time Session
8:00 – 8:30 AM ET
Arrivals and Breakfast
8:30 – 8:45 AM ET
Welcome, Objectives, Introduction + SITC Biotech Committee Update
Moderator: Zhen Su, MD, MBA - Marengo Therapeutics
Speakers:
  • Eric Dimise, PhD - NYSE
  • James Gulley, MD, PhD, FACP - National Cancer Institute (NCI)
8:45 – 9:05 AM ET
Outcomes from Pre-Meeting Events
Summary of the collaborative programming on Thursday, June 25th
Moderator: Zhen Su, MD, MBA - Marengo Therapeutics
9:05 – 9:45 AM ET
Tour of the NYSE Floor + Bell Ringing
9:45 – 10:05 AM ET
Presentation: Healthcare Capital Markets and Strategic Landscapes
10:10 – 10:30 AM ET
Keynote Presentation: IO Dealmaking and Partnership Trends
Financing, investing, dealmaking of biotech innovation in immuno-oncology
Speaker:
  • Andrew Baum, MD - Pfizer
10:30 – 10:50 AM ET
Keynote Q&A
10:50 – 11:00 AM ET
Coffee Break
11:00 – 11:40 AM ET
Considerations of Launching a New Company
Moderator: David Kaufman, MD, PhD - Third Rock Ventures
Speakers:
  • Eric Dimise, PhD - NYSE
  • Holger Kissel, PhD
  • Beverly Lu, PhD - Yosemite
  • Lex Johnson, PhD - Dispatch Bio
  • Michael Rosenzweig, PhD - Abbvie
11:45 AM – 12:25 PM ET
Liquidity in Biotechs, Mergers and Acquisitions
How companies navigate strategic choices in public markets
Speakers:
  • Paul Peter Tak, MD, PhD, FMedSci - Candel Therapeutics
12:25 – 1:20 PM ET
Lunch
1:20 – 2:00 PM ET
China's Strategy for Western IO Biotech
Insight into IST pathways and operational innovation
Moderator: Holger Kissel, PhD - BioNTech
Speakers:
  • David Kolesky, PhD - MPM
  • Leon 'Jun' Tang, PhD - InScienceWeTrust BioAdvisory
  • Lei Lei Wu - Endpoint News
2:05 – 2:45 PM ET
Developing AI Assisted Computational Therapies
The state of AI investments through clinical and developmental landscapes
Moderator: Alexandra Snyder, MD - Merck
Speakers:
  • Dinesh de Alwis, PhD - Generate Biomedicines
  • Vicki Goodman, MD - Recursion
  • John E. Connolly, PhD - PICI
  • Hamish Wright, PhD 
2:50 – 3:30 PM ET
The Future of Personalized Medicine and Cancer Therapies
Differentiating checkpoint inhibitors and novel combinations · ADCs, PD1/VEGF, in vivo CAR T and TCEs
Moderator: Kasia Urbanska, PhD - BMS
Speakers:
  • Uli Bialucha, PhD - Xilio Therapeutics
  • Jenny Hamilton - Azalea Therapeutics
  • Michael Rosenzweig, PhD - Abbvie
  • Dimitris Skokos, PhD - Regeneron
3:30 – 3:35 PM ET
Closing Remarks and Synthesis
Moderator: Zhen Su, MD, MBA - Marengo Therapeutics

Registration Rates

In-Person Registration Rates

Early Rate
Ends May 18		 Regular Rate
Industry Member $400.00 $450.00
Industry Non-Member $800.00 $850.00
Member $200.00 $250.00
Non-Member $400.00 $450.00
Student Member $50.00 $100.00
Student Non-Member $100.00 $150.00

Virtual Registration Rates

Industry Member $300.00
Industry Non-Member $600.00
Member $150.00
Non-Member $300.00
Student Member $38.00
Student Non-Member $75.00

What you missed last year.

Innovation doesn't wait. Don't miss groundbreaking, cross-sector meetings with leaders across biotech, finance and regulatory agencies.